Cell Therapeutics, Inc. provided earnings guidance for the month ended December 31, 2012. For the period, the company expects operating expense of $8,966,000, loss from operations of $8,966,000, EBITDA of $8,393,000, depreciation and amortization of $195,000, interest expense of $1,000 and net loss attributable to common shareholders of $8,589,000. Estimated research and development expenses were $3.6 million for the month of December 2012 respectively.
1st Jan change | Capi. | |
---|---|---|
+39.64% | 53.67B | |
+33.67% | 38.86B | |
-7.70% | 38.76B | |
-10.77% | 27.27B | |
+12.29% | 25.91B | |
-17.83% | 20.29B | |
+34.93% | 12.78B | |
+29.25% | 12.18B | |
-2.86% | 11.96B |